Market Chatter: Nourish Raises $100 Million to Help Patients Maintain GLP-1 Weight-Loss Results
Idag, 14:27
Idag, 14:27
08:27 AM EDT, 05/19/2026 (MT Newswires) -- Nourish, a nutrition counseling startup focused on supporting patients using GLP-1 weight-loss drugs, raised $100 million in a Series C funding round led by Menlo Ventures, Bloomberg reported Tuesday.
The funding round, which also included existing investors such as Thrive Capital, Index Ventures and JPMorgan Chase's (JPM) growth equity arm, valued the company at about $1.75 billion, the report said, citing a person familiar with the matter.
Nourish plans to use the new funding to expand its dietitian network and invest further in artificial intelligence tools for patient support, Bloomberg added, citing Chief Executive Aidan Dewar.
JPMorgan Chase did not immediately respond to MT Newswires'request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Idag, 14:27
08:27 AM EDT, 05/19/2026 (MT Newswires) -- Nourish, a nutrition counseling startup focused on supporting patients using GLP-1 weight-loss drugs, raised $100 million in a Series C funding round led by Menlo Ventures, Bloomberg reported Tuesday.
The funding round, which also included existing investors such as Thrive Capital, Index Ventures and JPMorgan Chase's (JPM) growth equity arm, valued the company at about $1.75 billion, the report said, citing a person familiar with the matter.
Nourish plans to use the new funding to expand its dietitian network and invest further in artificial intelligence tools for patient support, Bloomberg added, citing Chief Executive Aidan Dewar.
JPMorgan Chase did not immediately respond to MT Newswires'request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Nibe
Evolution
Nibe
Evolution
1 DAG %
Senast
OMX Stockholm 30
0,25%
(16:17)
OMX Stockholm 30
1 DAG %
Senast
3 063,48